The Hyperloop train levitates reaches 1000 kilometers per hour completes its first Test trip with passengers: Virgin Hyperloop has completed its first Test trip with passengers.
The company's Chief Technology Officer, Josh Giegel, and its passenger experience director, Sara Luchian, starred in a first Test trip of this developing train that levitates on magnetic rails and is capable of reaching speeds in excess of 1,000 kilometers per hour.
Although in this Test trip, which took place this Sunday, the vehicle reached 172 kilometers per hour on the Test rails of the Hyperloop facility, the DevLoop, in Las Vegas (USA).
Reuters has echoed this "key" news in the security of a technology that hopes to transform the transport of goods and people. "I had the real pleasure of seeing history made before my eyes," Sultan Ahmed in Sulayem, President of Virgin Hyperloop and corporate president and CEO of DP World, explained afterwards.
Hyperloop had already made up to 400 Test trips without humans. The company promises trips between Washington and New York in half an hour, which would be twice as fast as a commercial plane and up to four times faster than a high-speed train.
Hyperloop train levitates reaches 1000 kilometers per hour
These tests come a month after Reuters also advanced that Virgin Hyperloocp will build a certification and experimentation Center in Virginia, USA, as the company advances in its certifications and hopes to begin its commercial operations in 10 years.
A Spanish company is also developing its own Hyperloop. It is about Zeleros, which began as a spinoff of the Polytechnic of Valencia. In 2014 it won the audience award of the European Institute of innovation and raised this summer an investment round of about 7 million euros to continue its development.
Precisely Virgin Hyperloop announced this summer that it was leaving its train development in Spain dead because of not having received aid. Until then, Madrid-Barcelona was considered as one of the first routes that could develop commercially.
Hyperloop train levitates reaches 1000 kilometers per hour
More news:
Europe, about to close the agreement with Pfizer to secure millions of doses of the vaccine after positive results on its effectiveness
The European Union is finalizing the signing of the agreement with Pfizer and its German partner, BioNTech, for the obtaining of millions of doses of its vaccine against coronavirus, a member of the European Parliament has told Reuters.
The statements have been made after it became known this same Monday that the vaccine candidate of the pharmaceutical Pfizer has managed to successfully overcome the final stage of its clinical trials, achieving a 90% effectiveness in the Prevention of covid-19 infections.
” According to my information, the contract is about to be signed, " assured Peter Liese, MEP who heads Health Affairs within the European People's party.
"There is an agreement under which Europeans will receive hundreds of millions of vaccines," he later added in a statement emailed to Reuters.
The European Commission reached an initial agreement with Pfizer at the beginning of September to secure a reserve of 200 million doses, with the option that the 27 member states could choose to purchase a further 100 million.
According to the information published at the time, the agreement will offer member countries the possibility of acquiring the vaccine and making donations to middle and low income countries or redirecting it to European countries.
Although for the moment the value of the operation has not been announced, since some fringes are missing to close that have led to the EU has not yet officially communicated it, the pharmaceutical giant has already made clear its intention to achieve economic benefits with the coronavirus vaccine.
In fact, Pfizer has reached a pact with the United States that places the price per dose at 19,50 dollars (about 16,5 euros), according to figures managed by the Financial Times.
It is not the only agreement the EU has reached on vaccines against coronavirus. The Commission has also closed the purchase of 300 million doses of the vaccine from the University of Oxford, AstraZeneca and has acquired 200 million doses of which develops Johnson & Johnson.
The body has also initiated talks with Moderna, Sanofi and CureVac in their intention to ensure that covid-19 vaccines reach European citizens as soon as possible.